Vinay Prasad, oncology’s gadfly-turned-CBER-director, will leave FDA (again)

Prasad’s rule by fiat spilled into accelerated approvals in hematology and oncology
Atara Bio’s Cokey Nguyen: Normally, FDA wants to help us succeed. Now, “we’re getting new guidance at the last minute and it’s not helping.”

On Jan. 9, Pierre Fabre Pharmaceuticals received a “complete response letter” from FDA: its application for the T-cell therapy tabelecleucel (Ebvallo) was getting a hard No.

FDA approves leucovorin for cerebral folate deficiency

FDA has approved leucovorin calcium tablets (Wellcovorin), expanding its use for the treatment of cerebral folate deficiency in adult and pediatric patients.

March 13, 2026

Vol.52 No.10

By Claire Marie Porter

In Brief

Vivek Subbiah to lead Early Drug Development Program at Stanford Cancer Institute

Vivek Subbiah has been appointed as the inaugural associate director for drug development and precision oncology at the Stanford Cancer Institute, with a planned start date in spring 2026.

March 13, 2026

Vol.52 No.10

In Brief

Lonny Yarmus named head of the Division of Subspecialty Medicine at MSK

Lonny Yarmus was appointed head of the Division of Subspecialty Medicine in the Department of Medicine at Memorial Sloan Kettering Cancer Center. A physician-scientist and internationally recognized leader in interventional pulmonology and procedural innovation, Yarmus is widely known for his expertise in minimally invasive diagnostics and therapeutics, outcomes research, and multidisciplinary program development.

March 13, 2026

Vol.52 No.10

In Brief

GRAIL announces retirement of CEO Bob Ragusa, appoints President Josh Ofman as successor

GRAIL has announced that Bob Ragusa will retire as CEO, effective June 1.

March 13, 2026

Vol.52 No.10

In Brief

Kim Rathmell named OSUCCC director, Pollock becomes director emeritus in planned leadership transition

W. Kimryn Rathmell, CEO of the James Cancer Hospital and Solove Research Institute, has also been named director of The Ohio State University Comprehensive Cancer Center in place of former Director Raphael E. Pollock, who has stepped down from the position he had held since November 2017 to become OSUCCC director emeritus.

March 06, 2026

Vol.52 No.09

Vinay Prasad, oncology’s gadfly-turned-CBER-director, will leave FDA (again)

YOU MAY BE INTERESTED IN

Prasad’s rule by fiat spilled into accelerated approvals in hematology and oncology
Atara Bio’s Cokey Nguyen: Normally, FDA wants to help us succeed. Now, “we’re getting new guidance at the last minute and it’s not helping.”

FDA approves leucovorin for cerebral folate deficiency

Vivek Subbiah to lead Early Drug Development Program at Stanford Cancer Institute

Lonny Yarmus named head of the Division of Subspecialty Medicine at MSK

GRAIL announces retirement of CEO Bob Ragusa, appoints President Josh Ofman as successor

Kim Rathmell named OSUCCC director, Pollock becomes director emeritus in planned leadership transition

Renew today!

Subscriber content

Never miss an issue!

Login

Vinay Prasad, oncology’s gadfly-turned-CBER-director, will leave FDA (again)

YOU MAY BE INTERESTED IN

Prasad’s rule by fiat spilled into accelerated approvals in hematology and oncologyAtara Bio’s Cokey Nguyen: Normally, FDA wants to help us succeed. Now, “we’re getting new guidance at the last minute and it’s not helping.”

FDA approves leucovorin for cerebral folate deficiency

Vivek Subbiah to lead Early Drug Development Program at Stanford Cancer Institute

Lonny Yarmus named head of the Division of Subspecialty Medicine at MSK

GRAIL announces retirement of CEO Bob Ragusa, appoints President Josh Ofman as successor

Kim Rathmell named OSUCCC director, Pollock becomes director emeritus in planned leadership transition

Never miss an issue!

Login

Prasad’s rule by fiat spilled into accelerated approvals in hematology and oncology
Atara Bio’s Cokey Nguyen: Normally, FDA wants to help us succeed. Now, “we’re getting new guidance at the last minute and it’s not helping.”